Free Trial

Genetic Technologies (GENE) Stock Price, News & Analysis

+0.08 (+3.51%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
11,019 shs
Average Volume
27,699 shs
Market Capitalization
$10.41 million
P/E Ratio
Dividend Yield
Price Target
GENE stock logo

About Genetic Technologies Stock (NASDAQ:GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

GENE Stock Price History

GENE Stock News Headlines

Appendix 4C & Quarterly Business Update – March 2024
Appendix 4C & Quarterly Business Update – March 2024
ADRs End Lower; Genetic Technologies Declines 23%
See More Headlines
Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$5.85 million
Book Value
$1.95 per share


Free Float
Market Cap
$10.14 million

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Simon Morriss
    Chief Executive Officer
  • Mr. Carl S. Stubbings BSc
    Chief Commercial Officer
  • Mr. Kevin Camilleri
    Chief Executive Officer of EasyDNA
  • Ms. Kathryn J. E. Andrews B.Com. (Age 57)
    C.P.A., M.A.I.C.D., CFO & Company Secretary
  • Mr. Paul Keith Mathieson Viney B. Bus
    FCI, FCPA, FGIA, Consultant

GENE Stock Analysis - Frequently Asked Questions

How have GENE shares performed in 2024?

Genetic Technologies' stock was trading at $2.40 on January 1st, 2024. Since then, GENE shares have decreased by 3.7% and is now trading at $2.31.
View the best growth stocks for 2024 here

When did Genetic Technologies' stock split?

Shares of Genetic Technologies reverse split on Monday, December 4th 2023. The 1-5 reverse split was announced on Monday, December 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Genetic Technologies own?
Who are Genetic Technologies' major shareholders?

Genetic Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include BNP Paribas Financial Markets (0.24%).

How do I buy shares of Genetic Technologies?

Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GENE) was last updated on 5/21/2024 by Staff

From Our Partners